The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Enbrel (Etanercept) and Biosimilar Market Research Report 2024

Global Enbrel (Etanercept) and Biosimilar Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739059

No of Pages : 93

Ask Your Query

Synopsis
Etanercept is a medication used to manage and treat autoimmune conditions such as plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. It is a biologic fusion protein in the TNF blocker class of medications.

Global Enbrel (Etanercept) and Biosimilar market is projected to reach US$ 8562.6 million in 2029, increasing from US$ 6350 million in 2022, with the CAGR of 3.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Enbrel (Etanercept) and Biosimilar market research.

Key manufacturers engaged in the Enbrel (Etanercept) and Biosimilar industry include Pfizer, Amgen, Samsung Bioepis, Novartis, 3s Bio and Lupin, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Enbrel (Etanercept) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Enbrel (Etanercept) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Enbrel (Etanercept) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Pfizer
  • Amgen
  • Samsung Bioepis
  • Novartis
  • 3s Bio
  • Lupin

Segment by Type

  • Syringe
  • Pen

Segment by Application

  • Hospital
  • Pharmacy
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Enbrel (Etanercept) and Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Enbrel (Etanercept) and Biosimilar Market Overview
1.1 Product Overview and Scope of Enbrel (Etanercept) and Biosimilar
1.2 Enbrel (Etanercept) and Biosimilar Segment by Type
1.2.1 Global Enbrel (Etanercept) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Syringe
1.2.3 Pen
1.3 Enbrel (Etanercept) and Biosimilar Segment by Application
1.3.1 Global Enbrel (Etanercept) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Enbrel (Etanercept) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Enbrel (Etanercept) and Biosimilar Revenue 2018-2029
1.4.2 Global Enbrel (Etanercept) and Biosimilar Sales 2018-2029
1.4.3 Global Enbrel (Etanercept) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Enbrel (Etanercept) and Biosimilar Market Competition by Manufacturers
2.1 Global Enbrel (Etanercept) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Enbrel (Etanercept) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Enbrel (Etanercept) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Enbrel (Etanercept) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Enbrel (Etanercept) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Enbrel (Etanercept) and Biosimilar, Product Type & Application
2.7 Enbrel (Etanercept) and Biosimilar Market Competitive Situation and Trends
2.7.1 Enbrel (Etanercept) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Enbrel (Etanercept) and Biosimilar Players Market Share by Revenue
2.7.3 Global Enbrel (Etanercept) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Enbrel (Etanercept) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Enbrel (Etanercept) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Enbrel (Etanercept) and Biosimilar Global Enbrel (Etanercept) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Enbrel (Etanercept) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Enbrel (Etanercept) and Biosimilar Sales by Region: 2024-2029
3.3 Global Enbrel (Etanercept) and Biosimilar Global Enbrel (Etanercept) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Enbrel (Etanercept) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Enbrel (Etanercept) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Enbrel (Etanercept) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Enbrel (Etanercept) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Enbrel (Etanercept) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Enbrel (Etanercept) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Enbrel (Etanercept) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Enbrel (Etanercept) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Enbrel (Etanercept) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Enbrel (Etanercept) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Enbrel (Etanercept) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Enbrel (Etanercept) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Enbrel (Etanercept) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Enbrel (Etanercept) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Enbrel (Etanercept) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Enbrel (Etanercept) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Enbrel (Etanercept) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Enbrel (Etanercept) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Enbrel (Etanercept) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Enbrel (Etanercept) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Enbrel (Etanercept) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Enbrel (Etanercept) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Enbrel (Etanercept) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Enbrel (Etanercept) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Enbrel (Etanercept) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Enbrel (Etanercept) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Enbrel (Etanercept) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Enbrel (Etanercept) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Enbrel (Etanercept) and Biosimilar Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amgen Enbrel (Etanercept) and Biosimilar Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Samsung Bioepis
6.3.1 Samsung Bioepis Corporation Information
6.3.2 Samsung Bioepis Description and Business Overview
6.3.3 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Samsung Bioepis Enbrel (Etanercept) and Biosimilar Product Portfolio
6.3.5 Samsung Bioepis Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Enbrel (Etanercept) and Biosimilar Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 3s Bio
6.5.1 3s Bio Corporation Information
6.5.2 3s Bio Description and Business Overview
6.5.3 3s Bio Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 3s Bio Enbrel (Etanercept) and Biosimilar Product Portfolio
6.5.5 3s Bio Recent Developments/Updates
6.6 Lupin
6.6.1 Lupin Corporation Information
6.6.2 Lupin Description and Business Overview
6.6.3 Lupin Enbrel (Etanercept) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Lupin Enbrel (Etanercept) and Biosimilar Product Portfolio
6.6.5 Lupin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Enbrel (Etanercept) and Biosimilar Industry Chain Analysis
7.2 Enbrel (Etanercept) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Enbrel (Etanercept) and Biosimilar Production Mode & Process
7.4 Enbrel (Etanercept) and Biosimilar Sales and Marketing
7.4.1 Enbrel (Etanercept) and Biosimilar Sales Channels
7.4.2 Enbrel (Etanercept) and Biosimilar Distributors
7.5 Enbrel (Etanercept) and Biosimilar Customers
8 Enbrel (Etanercept) and Biosimilar Market Dynamics
8.1 Enbrel (Etanercept) and Biosimilar Industry Trends
8.2 Enbrel (Etanercept) and Biosimilar Market Drivers
8.3 Enbrel (Etanercept) and Biosimilar Market Challenges
8.4 Enbrel (Etanercept) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock